Business Relations Table - o4.fyi ()

Anmelden Gast|Guest
Beispiel: brt.php?search=wide&s=wide&p=adjective&o=wideness

Domain-Statistiken für "trialstat.com"

173
Business Relations
169
Eindeutige Domains
20
Gefundene Einträge
BR-Relations: 173
From Domain Role To Domain Path Aktionen
/directory/FindStartsWith
/acdm26-exhibitors/
/fda/regenxbio-delay-could-put-denali-in-pole-position-for-hunter-syndrome-approval
/2023/03/pyxis-oncology-announces-dosing-of-first-subject-in-phase-1-trial-of-pyx-201-a-novel-adc-for-solid-tumors/
/2023/05/fractyl-health-unveils-groundbreaking-pre-clinical-proof-of-concept-results-for-its-rejuva-pancreatic-gene-therapy-platform-for-metabolic-diseases-at-the-american-society-of-gene-cell-ther/
/2023/05/new-gene-therapy-being-developed-at-university-of-toronto-could-treat-ms/
/2023/07/adamis-pharmaceuticals-to-fund-zimhi-clinical-study-with-university-of-leiden-opioid-expert/
/2023/09/student-researcher-collaborating-with-indigenous-community-to-improve-cancer-screening/
/2023/09/student-researcher-collaborating-with-indigenous-community-to-improve-cancer-screening/
/2023/09/zynerba-pharmaceuticals-presents-positive-data-from-phase-2-inspire-trial-in-22q11-2-deletion-syndrome-at-the-society-for-the-study-of-behavioural-phenotypes-ssbp-25th-international-research-symposi/
/2023/10/inmagene-doses-first-patient-in-phase-2a-trial-of-img-007-an-anti-ox40-monoclonal-antibody-with-an-extended-half-life-for-the-treatment-of-alopecia-areata/
/2023/10/promising-preclinical-narazaciclib-data-presented-at-mcl-meeting/
/2023/11/world-first-gene-therapy-for-2-blood-disorders-sickle-cell-and-thalassemia-approved/
/2023/11/world-first-gene-therapy-for-2-blood-disorders-sickle-cell-and-thalassemia-approved/
/2023/11/biovectra-launches-specialized-capabilities-in-mrna-drug-product-development-and-biomanufacturing/
/2023/11/neuroone-picks-up-patent-for-drug-delivery-device/
/2023/11/neuroone-picks-up-patent-for-drug-delivery-device/
/2023/12/caribou-biosciences-provides-regulatory-update-on-cb-010-pivotal-plan-with-phase-3-trial-initiation-expected-by-ye-2024/
/2023/12/maze-therapeutics-announces-initiation-of-dosing-in-phase-1-trial-evaluating-mze829-a-novel-oral-apol1-inhibitor-as-a-potential-treatment-for-apol1-kidney-disease/
/2023/12/neurosense-reports-new-data-statistically-significant-clinical-efficacy-in-phase-2b-als-trial/